Please ensure Javascript is enabled for purposes of website accessibility

Intercept Pharmaceuticals Notches Convincing Q2 Beats

By Eric Volkman - Aug 11, 2020 at 9:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A better-than-expected quarter helps ease the pain of a recent FDA denial.

Intercept Pharmaceuticals (ICPT 2.62%) isn't exactly having a summer to remember, but the second-quarter results it delivered early Monday were quite encouraging.

For the period, the company's total revenue came in at $77.2 million, up 16% year over year. Its net loss narrowed over that stretch of time to $63.3 million ($1.92 per share) from its Q2 2019 deficit of $71.4 million.

On average, analysts had estimated Intercept would book just under $72.2 million in revenue, and suffer a $2.92 per share bottom-line loss.

The hallway of a hospital.

Image source: Getty Images.

The one drug Intercept has on the market, Ocaliva, treats primary biliary cholangitis (PBC), a rare autoimmune disease affecting the liver. Originally approved by the Food and Drug Administration in 2016, Ocaliva was responsible for all of the company's Q2 revenue.

"Our PBC business achieved its highest quarterly net sales to date in the second quarter," noted CEO Mark Pruzanski. "We plan to continue to invest in our growing PBC business."

In its earnings release, Intercept guided for $300 million to $320 million in net sales for Ocaliva.

In late June, Intercept suffered a setback when its latest regulatory application failed. This was for Ocaliva to be cleared for use as a treatment for liver fibrosis deriving from non-alcoholic steatohepatitis (NASH) -- the most severe form of non-alcoholic fatty liver disease (NAFLD). The FDA essentially rejected this via a complete response letter. The company said it aims to file an updated application.

Investors were satisfied with Intercept's latest quarterly results; they bid the stock up by more than 8% on Monday, a rate that easily topped the gains of the wider equity market.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Intercept Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
$16.85 (2.62%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.